ASH 2023 | Subcutaneous mosunetuzumab as first-line therapy in high tumor-burden follicular lymphoma
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the first results of a multicenter Phase II study (NCT05389293) investigating subcutaneous (SC) mosunetuzumab as first-line therapy for patients with high tumor-burden follicular lymphoma (FL). This immunotherapy approach was well tolerated, with the most common adverse events (AEs) being mild cytokine release syndrome (CRS) and injection site reactions. Preliminary efficacy results are highly encouraging, with a best overall response rate (ORR) of 96% and a complete response (CR) rate of 81%. Importantly, high response rates are consistent across high-risk patient subsets. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AstraZeneca, Genentech, Abbvie, Ipsen, ADC Therapeutics, Seagen
Consultancy: Genmab, Roche, Genentech, Abbvie, Evolveimmune
Honoraria: Genmab, Genentech, Abbvie
Travel Expenses: Genmab, Abbvie
Research Funding: Genmab, Roche, Genentech, Abbvie, Innate Pharma
